Achilles Therapeutics Ownership
| ACHL Stock | USD 1.06 0.01 0.93% |
Shares in Circulation | First Issued 2018-12-31 | Previous Quarter 40.4 M | Current Value 40.4 M | Avarage Shares Outstanding 28.3 M | Quarterly Volatility 14.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Achilles |
Achilles Stock Ownership Analysis
About 59.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. Achilles Therapeutics PLC recorded a loss per share of 1.66. The entity had not issued any dividends in recent years. Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company was founded in 2016 and is headquartered in London, the United Kingdom. Achilles Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Achilles Therapeutics PLC please contact Iraj Ali at 44 20 8154 4600 or go to https://www.achillestx.com.Besides selling stocks to institutional investors, Achilles Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Achilles Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Achilles Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Achilles Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 7.0% of Achilles Therapeutics PLC are currently held by insiders. Unlike Achilles Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Achilles Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Achilles Therapeutics' insider trades
Achilles Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Achilles Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Achilles Therapeutics PLC backward and forwards among themselves. Achilles Therapeutics' institutional investor refers to the entity that pools money to purchase Achilles Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Virtu Financial Llc | 2024-06-30 | 22.8 K | Geode Capital Management, Llc | 2024-09-30 | 21.6 K | Two Sigma Investments Llc | 2024-09-30 | 21.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 17.9 K | Baader Bank Inc | 2024-09-30 | 14.2 K | Hrt Financial Llc | 2024-06-30 | 10.9 K | Brave Asset Management Inc | 2024-09-30 | 10 K | Rhumbline Advisers | 2024-06-30 | 4.5 K | Arcadia Investment Management Corp | 2024-09-30 | 3 K | Syncona Portfolio Ltd. | 2024-09-30 | 11.1 M | Bml Capital Management Llc | 2024-09-30 | 4.1 M |
Achilles Therapeutics Outstanding Bonds
Achilles Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Achilles Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Achilles bonds can be classified according to their maturity, which is the date when Achilles Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ACE INA HLDGS Corp BondUS00440EAH09 | View | |
| ACE INA HLDGS Corp BondUS00440EAQ08 | View | |
| ACE INA HLDGS Corp BondUS00440EAW75 | View | |
| ACE INA HLDGS Corp BondUS00440EAV92 | View | |
| ACE INA HLDGS Corp BondUS00440EAS63 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| ACI Worldwide 575 Corp BondUS004498AB73 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.